Dabigatran etexilate for thromboembolic prophylaxis in non-valvular atrial fibrillation: the RE-LY study and substudies with commentary

References

• Miyasaka Y, Barnes ME, Gersh BJ et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation 114(2), 119–125 (2006).
   PubMed Web of Science ®Google Scholar
• Roger VL, Go AS, Lloyd-Jones DM et al. Heart disease and stroke statistics–2012 update: a report from the American Heart Association. Circulation 125(1), e2–e220 (2012).
   PubMed Web of Science ®Google Scholar
• Benjamin EJ, Levy D, Vaziri SM, D'agostino RB, Belanger AJ, Wolf PA. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA 271(11), 840–844 (1994).
   PubMed Web of Science ®Google Scholar
• Dorian P, Jung W, Newman D et al. The impairment of health-related quality of life in patients with intermittent atrial fibrillation: implications for the assessment of investigational therapy. J. Am. Coll. Cardiol. 36(4), 1303–1309 (2000).
   PubMed Web of Science ®Google Scholar
• Hamer ME, Blumenthal JA, Mccarthy EA, Phillips BG, Pritchett EL. Quality-of-life assessment in patients with paroxysmal atrial fibrillation or paroxysmal supraventricular tachycardia. Am. J. Cardiol. 74(8), 826–829 (1994).
   Google Scholar
• Kilander L, Andren B, Nyman H, Lind L, Boberg M, Lithell H. Atrial fibrillation is an independent determinant of low cognitive function: a cross-sectional study in elderly men. Stroke 29(9), 1816–1820 (1998).
   PubMed Web of Science ®Google Scholar
• Ott A, Breteler MM, De Bruyne MC, Van Harskamp F, Grobbee DE, Hofman A. Atrial fibrillation and dementia in a population-based study. The Rotterdam Study. Stroke 28(2), 316–321 (1997).
   PubMed Web of Science ®Google Scholar
• Gronefeld GC, Hohnloser SH. Heart failure complicated by atrial fibrillation: mechanistic, prognostic, and therapeutic implications. J. Cardiovasc. Pharmacol. Ther. 8(2), 107–113 (2003).
   Google Scholar
• Cha YM, Redfield MM, Shen WK, Gersh BJ. Atrial fibrillation and ventricular dysfunction: a vicious electromechanical cycle. Circulation 109(23), 2839–2843 (2004).
   PubMed Web of Science ®Google Scholar
• Grogan M, Smith HC, Gersh BJ, Wood DL. Left ventricular dysfunction due to atrial fibrillation in patients initially believed to have idiopathic dilated cardiomyopathy. Am. J. Cardiol. 69(19), 1570–1573 (1992).
   PubMed Web of Science ®Google Scholar
• Cairns JA, Connolly SJ. Nonrheumatic atrial fibrillation. Risk of stroke and role of antithrombotic therapy. Circulation 84(2), 469–481 (1991).
   PubMed Web of Science ®Google Scholar
• Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 22(8), 983–988 (1991).
   PubMed Web of Science ®Google Scholar
• Benjamin EJ, Wolf PA, D'agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation 98(10), 946–952 (1998).
   PubMed Web of Science ®Google Scholar
• Kim MH, Johnston SS, Chu BC, Dalal MR, Schulman KL. Estimation of total incremental health care costs in patients with atrial fibrillation in the United States. Circ. Cardiovasc. Qual. Outcomes 4(3), 313–320 (2011).
   PubMed Web of Science ®Google Scholar
• Prevalence and most common causes of disability among adults–United States, 2005. MMWR Morb. Mortal. Wkly. Rep. 58(16), 421–426 (2009).
   Google Scholar
• Rosamond W, Flegal K, Furie K et al. Heart disease and stroke statistics–2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 117(4), e25–e146 (2008).
   PubMed Web of Science ®Google Scholar
• Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation: a major contributor to stroke in the elderly. The Framingham Study. Arch.Intern. Med. 147(9), 1561–1564 (1987).
   PubMedGoogle Scholar
• Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann. Intern. Med. 146(12), 857–867 (2007).
   PubMed Web of Science ®Google Scholar
• Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch. Intern. Med. 154(13), 1449–1457 (1994).
   Google Scholar
• Hankey GJ, Eikelboom JW. Dabigatran etexilate: a new oral thrombin inhibitor. Circulation 123(13), 1436–1450 (2011).
   PubMed Web of Science ®Google Scholar
• Ahrens I, Lip GY, Peter K. New oral anticoagulant drugs in cardiovascular disease. Thromb. Haemost. 104(1), 49–60 (2010).
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Pogue J, Eikelboom J et al. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation 118(20), 2029–2037 (2008).
   PubMed Web of Science ®Google Scholar
• Zimetbaum PJ, Thosani A, Yu HT et al. Are atrial fibrillation patients receiving warfarin in accordance with stroke risk? Am. J. Med. 123(5), 446–453 (2010).
   Google Scholar
• Van Ryn J, Stangier J, Haertter S et al. Dabigatran etexilate–a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb. Haemost. 103(6), 1116–1127 (2010).
   PubMed Web of Science ®Google Scholar
• Stangier J. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin. Pharmacokinet. 47(5), 285–295 (2008).
   PubMed Web of Science ®Google Scholar
• Pradaxa®[prescribing information], package insert. Boehringer-IngelheimPharmaceuticals, Inc., Ridgefield, CT, USA.
   Google Scholar
• Ezekowitz MD, Reilly PA, Nehmiz G et al. Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study). Am. J. Cardiol. 100(9), 1419–1426 (2007).
   PubMed Web of Science ®Google Scholar
• Ezekowitz MD, Connolly S, Parekh A et al. Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran. Am. Heart J. 157(5), 805–810, 810.e801–e802 (2009).
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Ezekowitz MD, Yusuf S et al. Dabigatran versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 361(12), 1139–1151 (2009).
   PubMed Web of Science ®Google Scholar
• Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 285(22), 2864–2870 (2001).
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Ezekowitz MD, Yusuf S, Reilly PA, Wallentin L. Newly identified events in the RE-LY trial. N. Engl. J. Med. 363(19), 1875–1876 (2010).
   PubMed Web of Science ®Google Scholar
• Mohapatra R, Tran M, Gore JM, Spencer FA. A review of the oral direct thrombin inhibitor ximelagatran: not yet the end of the warfarin era. Am. Heart J. 150(1), 19–26 (2005).
   Google Scholar
• Albers GW, Diener HC, Frison L et al. Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. JAMA 293(6), 690–698 (2005).
   PubMed Web of Science ®Google Scholar
• Eikelboom JW, Wallentin L, Connolly SJ et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation 123(21), 2363–2372 (2011).
   PubMed Web of Science ®Google Scholar
• Hohnloser SH, Oldgren J, Yang S et al. Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial. Circulation 125(5), 669–676 (2012).
   PubMed Web of Science ®Google Scholar
• Weigner MJ, Caulfield TA, Danias PG, Silverman DI, Manning WJ. Risk for clinical thromboembolism associated with conversion to sinus rhythm in patients with atrial fibrillation lasting less than 48 hours. Ann. Intern. Med. 126(8), 615–620 (1997).
   PubMed Web of Science ®Google Scholar
• Berger M, Schweitzer P. Timing of thromboembolic events after electrical cardioversion of atrial fibrillation or flutter: a retrospective analysis. Am. J. Cardiol. 82(12), 1545–1547, a1548 (1998).
   PubMed Web of Science ®Google Scholar
• Bjerkelund CJ, Orning OM. The efficacy of anticoagulant therapy in preventing embolism related to D.C. electrical conversion of atrial fibrillation. Am. J. Cardiol. 23(2), 208–216 (1969).
   PubMed Web of Science ®Google Scholar
• Fatkin D, Kuchar DL, Thorburn CW, Feneley MP. Transesophageal echocardiography before and during direct current cardioversion of atrial fibrillation: evidence for “atrial stunning” as a mechanism of thromboembolic complications. J. Am. Coll. Cardiol. 23(2), 307–316 (1994).
   Google Scholar
• Fuster V, Ryden LE, Cannom DS et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). J. Am. Coll. Cardiol. 48(4), 854–906 (2006).
   PubMed Web of Science ®Google Scholar
• Manning WJ, Silverman DI, Katz SE et al. Temporal dependence of the return of atrial mechanical function on the mode of cardioversion of atrial fibrillation to sinus rhythm. Am. J. Cardiol. 75(8), 624–626 (1995).
   Google Scholar
• Grimm RA, Stewart WJ, Arheart K, Thomas JD, Klein AL. Left atrial appendage “stunning” after electrical cardioversion of atrial flutter: an attenuated response compared with atrial fibrillation as the mechanism for lower susceptibility to thromboembolic events. J. Am. Coll. Cardiol. 29(3), 582–589 (1997).
   Google Scholar
• Nagarakanti R, Ezekowitz MD, Oldgren J et al. Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion. Circulation 123(2), 131–136 (2011).
   PubMed Web of Science ®Google Scholar
• Oldgren J, Alings M, Darius H et al. Risks for stroke, bleeding, and death in patients with atrial fibrillation receiving dabigatran or warfarin in relation to the CHADS2 score: a subgroup analysis of the RE-LY trial. Ann. Intern. Med. 155(10), 660–667, W204 (2011).
   PubMed Web of Science ®Google Scholar
• Fuster V, Ryden LE, Cannom DS et al. 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 123(10), e269–e367 (2011).
   PubMed Web of Science ®Google Scholar
• Wallentin L, Yusuf S, Ezekowitz MD et al. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet 376(9745), 975–983 (2010).
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Wallentin L, Ezekowitz MD et al. The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study. Circulation 128(3), 237–243 (2013).
   PubMed Web of Science ®Google Scholar
• Pisters R, Lane DA, Nieuwlaat R, De Vos CB, Crijns HJGM, Lip GYH. A novel user-friendly score (has-bled) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the euro heart survey. Chest 138(5), 1093–1100 (2010).
   PubMed Web of Science ®Google Scholar
• Gage BF, Yan Y, Milligan PE et al. Clinical classification schemes for predicting hemorrhage:results from the National Registry of Atrial Fibrillation (NRAF). Am. Heart J. 151(3), 713–719 (2006).
   PubMed Web of Science ®Google Scholar
• Fang MC, Go AS, Chang Y et al. A new risk scheme to predict warfarin-associated hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study. J. Am. Coll. Cardiol. 58(4), 395–401 (2011).
   PubMed Web of Science ®Google Scholar
• Piccini JP, Stevens SR, Chang Y et al. Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohorts. Circulation 127(2), 224–232 (2013).
   PubMed Web of Science ®Google Scholar
• Olesen JB, Lip GY, Kamper AL et al. Stroke and bleeding in atrial fibrillation with chronic kidney disease. N. Engl. J. Med. 367(7), 625–635 (2012).
   PubMed Web of Science ®Google Scholar
• Hariharan S, Madabushi R. Clinical pharmacology basis of deriving dosing recommendations for dabigatran in patients with severe renal impairment. J. Clin.Pharmacol. 52(Suppl. 1), S119–S125 (2012).
   Google Scholar
• Beasley BN, Unger EF, Temple R. Anticoagulant Options — Why the FDA approved a higher but not a lower dose of dabigatran. N. Engl. J. Med. 364(19), 1788–1790 (2011).
   PubMed Web of Science ®Google Scholar
• Larsen TB, Rasmussen LH, Skjoth F et al. Efficacy and safety of dabigatran etexilate and warfarin in “real-world” patients with atrial fibrillation: a prospective nationwide cohort study. J. Am. Coll. Cardiol. 61(22), 2264–2273 (2013).
   PubMed Web of Science ®Google Scholar
• Dentali F, Riva N, Crowther M, Turpie AG, Lip GY, Ageno W. Efficacy and safety of the novel oral anticoagulants in atrial fibrillation: a systematic review and meta-analysis of the literature. Circulation 126(20), 2381–2391 (2012).
   PubMed Web of Science ®Google Scholar
• Lip GY, Lane DA. Does warfarin for stroke thromboprophylaxis protect against MI in atrial fibrillation patients? Am. J. Med. 123(9), 785–789 (2010).
   PubMed Web of Science ®Google Scholar
• Uchino K, Hernandez AV. Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials. Arch.Intern. Med. 172(5), 397–402 (2012).
   PubMed Web of Science ®Google Scholar
• Shah SV, Gage BF. Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation. Circulation 123(22), 2562–2570 (2011).
   PubMed Web of Science ®Google Scholar
• Chang DN, Dager WE, Chin AI. Removal of dabigatran by hemodialysis. Am. J. Kidney Dis. 61(3), 487–489 (2013).
   PubMed Web of Science ®Google Scholar
• Singh T, Maw TT, Henry BL et al. Extracorporeal therapy for dabigatran removal in the treatment of acute bleeding: a single center experience. Clin . J. Am. Soc. Nephrol. 8(9), 1533–1539 (2013).
   PubMed Web of Science ®Google Scholar
• Wanek MR, Horn ET, Elapavaluru S, Baroody SC, Sokos G. Safe use of hemodialysis for dabigatran removal before cardiac surgery. Ann.Pharmacother. 46(9), e21 (2012).
   Google Scholar
• Schiele F, Van Ryn J, Canada K et al. A specific antidote for dabigatran: functional and structural characterization. Blood 121(18), 3554–3562 (2013).
   PubMed Web of Science ®Google Scholar
• Van Ryn J, Litzenburger T, Schurer J. Abstract 9928: Reversal of anticoagulant activity of dabigatran and dabigatran-induced bleeding in rats by a specific antidote (antibody fragment). Circulation 126, Abstract 9928 (2012).
   Google Scholar
• Lakkireddy D, Reddy YM, Di Biase L et al. Feasibility and safety of dabigatran versus warfarin for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registry. J. Am. Coll. Cardiol. 59(13), 1168–1174 (2012).
   PubMed Web of Science ®Google Scholar
• Ichiki H, Oketani N, Ishida S et al. The Incidence of Asymptomatic Cerebral Microthromboembolism after Atrial Fibrillation Ablation: Comparison of Warfarin and Dabigatran. Pacing Clin. Electrophysiol. () (2013) (E pub ahead of print).
   Google Scholar
• Bassiouny M, Saliba W, Rickard J et al. Use of dabigatran for periprocedural anticoagulation in patients undergoing catheter ablation for atrial fibrillation. Circ. Arrhythm. Electrophysiol. 6(3), 460–466 (2013).
   PubMed Web of Science ®Google Scholar
• Haines DE, Mead-Salley M, Salazar M et al. Dabigatran versus warfarin anticoagulation before and after catheter ablation for the treatment of atrial fibrillation. J. Interv. Card. Electrophysiol. 37(3), 233–239 (2013).
   PubMed Web of Science ®Google Scholar
• Providencia R, Albenque JP, Combes S et al. Safety and efficacy of dabigatran versus warfarin in patients undergoing catheter ablation of atrial fibrillation: a systematic review and meta-analysis. Heart () (2013) (Epub ahead of print).
   Google Scholar
• Stangier J, Feuring M. Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran. Blood Coagul. Fibrinolysis 23(2), 138–143 (2012).
   PubMed Web of Science ®Google Scholar
• Pare G, Eriksson N, Lehr T et al. Genetic determinants of dabigatran plasma levels and their relation to bleeding. Circulation 127(13), 1404–1412 (2013).
   PubMed Web of Science ®Google Scholar
• Lip GY, Frison L, Halperin JL, Lane DA. Identifying patients at high risk for stroke despite anticoagulation: a comparison of contemporary stroke risk stratification schemes in an anticoagulated atrial fibrillation cohort. Stroke 41(12), 2731–2738 (2010).
   PubMed Web of Science ®Google Scholar
• Glotzer TV, Hellkamp AS, Zimmerman J et al. Atrial high rate episodes detected by pacemaker diagnostics predict death and stroke: report of the Atrial Diagnostics Ancillary Study of the MOde Selection Trial (MOST). Circulation 107(12), 1614–1619 (2003).
   PubMed Web of Science ®Google Scholar
• Glotzer TV, Daoud EG, Wyse DG et al. The relationship between daily atrial tachyarrhythmia burden from implantable device diagnostics and stroke risk: the TRENDS study. Circ. Arrhythm. Electrophysiol. 2(5), 474–480 (2009).
   PubMed Web of Science ®Google Scholar
• Botto GL, Padeletti L, Santini M et al. Presence and duration of atrial fibrillation detected by continuous monitoring: crucial implications for the risk of thromboembolic events. J. Cardiovasc. Electrophysiol. 20(3), 241–248 (2009).
   PubMed Web of Science ®Google Scholar
• Healey JS, Connolly SJ, Gold MR et al. Subclinical atrial fibrillation and the risk of stroke. N. Engl. J. Med. 366(2), 120–129 (2012).
   PubMed Web of Science ®Google Scholar